About TScan Therapeutics
TScan Therapeutics is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. Its proprietary, high-throughput discovery platform enables the rapid, genome-wide identification of peptide antigen targets of T cell receptors, supporting programs in hematologic malignancies and solid tumors. Lead candidates include TSC-101 for AML, MDS, and ALL patients undergoing allogeneic hematopoietic cell transplantation.
Company details
Funding
Total raised
$180M
Last stage
Series C
Investors
Founders
Lea Hachigian
Co-founder of TScan Therapeutics and Longwood Fund Principal. Named in Forbes 2020 30 Under 30 list. Led TScan's strategy to generate novel immunotherapies based on TCR discovery technology.
Tomasz Kula
Co-founder of TScan Therapeutics and Ph.D. scientist. Developed TScan's core TCR discovery technology in the laboratory of Dr. Stephen Elledge at Harvard Medical School. Named in Forbes 2020 30 Under 30 list.
Christoph Westphal
Co-founder and startup CEO of TScan Therapeutics.
Stephen Elledge
Pioneering scientist at Harvard Medical School and HHMI whose breakthrough TCR discovery technology formed the scientific foundation for TScan Therapeutics.
Gavin MacBeath
Has two decades of experience in academia and industry; previously Co-founder and SVP of Discovery at Merrimack Pharmaceuticals and CSO at Abpro.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.